Trial
NCT03419130
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Merck Sharp & Dohme LLC
Condition
Infiltrating Bladder Urothelial Carcinoma
Intervention
Hypofractionated Radiation Therapy
Why stopped
Study withdrawn prior to patient enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-07